Studies on the pathogenesis and anti-VEGF treatment of retinopathy of prematurity

从11名患有ROP的婴儿中收集血清样品，这些婴儿在注射前和注射后1天、1周和2周接受玻璃体内注射贝伐单抗。采用酶联免疫吸附法测定患者血清中贝伐珠单抗和VEGF浓度。结果，玻璃体内注射总计0.5 mg贝伐珠单抗之前和之后1天、1周和2周的贝伐珠单抗血清浓度分别为0、195、946 L和1214（ng/mL）。玻璃体内注射贝伐珠单抗0.5 mg之前和之后1天、1周和2周的血清VEGF浓度分别为1628、427、246和269（pg/mL）。贝伐珠单抗血清浓度与VEGF血清浓度呈显著负相关（r= 0.575，P=0.0125）。这些结果表明，贝伐单抗可以从眼睛逃逸到体循环中，并降低ROP婴儿血清VEGF水平。

Serum samples were collected from 11 infants with ROP who had received intravitreal bevacizumab injection before and 1 day, 1 week, and 2 weeks after the injection. The serum concentrations of bevacizumab and VEGF were measured by enzyme-linked immunosorbent assay. As a result, the serum concentration of bevacizumab before and 1 day, 1week, and 2 weeks after a total of 0.5 mg of intravitreal bevacizumab was 0, 195, 946L, and 1214 (ng/mL), respectively. The serum concentration of VEGF before and 1 day, 1 week, and 2 weeks after a totalof 0.5 mg intravitreal bevacizumab was 1628, 427, 246, and 269 (pg/mL), respectively. There was a significant negative correlation (r= 0.575, P=0.0125) between the serum concentration of bevacizumab and VEGF. These results indicate that bevacizumab can escape from the eye into the systemiccirculation and reduce the serum level of VEGF in infants with ROP.